 |
 |
 |
 |
 |
Lymphocyte Response Assay (LRA) by ELISA/ACT® tests provide patient-specific information about all delayed hypersensitivity (DTH) / delayed allergy pathways. Our proprietary tests can be coupled with unique, individualized treatment interpretation guides to facilitate sustained remissions. The approach is based on proven clinical RCT controlled trials or case studies in managing people with chronic autoimmune and immune dysfunction syndromes.
|
|
These tests are unique because they are:
 Successful randomized controlled studies,
Case-controlled studies reported quarterly,
More than 20 years of proven clinical success,
Exceptional service to top clinicians everywhere, and
CLIA certified since 1990.
The treatment guide addresses the causes (rather than the symptoms) and includes recommendations to facilitate remission and recovery.
Identifying the patient’s specific sensitivities (delayed allergies), those that burden the immune system, is a clinical breakthrough. Patients experience a dramatic improvement in the quality of their life as a result of treatment protocols developed and clinically validated by ELISA/ACT Biotechnologies LLC (EAB).
|
|
|
 |
 |
 |
 |
 |
 |
|
|
Home
Who We Are
Why EAB
EAB Tests
Getting Started
Referral Network